A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis

Robert M. Pascuzzi, Jeremy Shefner, Amy S. Chappell, John S. Bjerke, Roy Tamura, Vinay Chaudhry, Lora Clawson, Lisa Haas, Jeffrey D. Rothstein

Research output: Contribution to journalArticle

88 Scopus citations

Abstract

Our objective was to determine if chronic treatment with the non-competitive AMPA antagonist talampanel is efficacious and safe in subjects with ALS. A double-blind, placebo-controlled, multicenter, randomized clinical trial of nine months treatment duration was conducted in 59 subjects with ALS, with 40 subjects receiving talampanel 50 mg p.o. t.i.d, and 19 subjects receiving placebo. Primary outcome measure was rate of decline in isometric arm strength (as measured by change in arm strength megaslope of the Tufts Quantitative Neuromuscular Exam (TQNE)). Other efficacy endpoints included rate of decline in respiratory function, isometric leg strength, bulbar function, fine motor function, the ALS Functional Rating Scale (ALSFRS), and survival. Secondary safety outcome measures were frequency of adverse events, neurological status, plasma concentration of talampanel, vital signs, routine laboratory tests, and electrocardiograms. Decline in muscle strength was 15% less in talampanel treated subjects, and decline in ALSFRS was 30% slower in talampanel treated subjects. Talampanel was safe in subjects with ALS. Mortality rates (8% talampanel, 5% placebo) and drug discontinuation rates (25% talampanel, 16% placebo) were similar in active treatment and placebo groups. Dizziness and somnolence occurred significantly more often in talampanel treated subjects. Although no efficacy measure reached statistical significance, there was a repeated trend toward slower decline in ALSFRS and isometric muscle strength in talampanel treated subjects. Talampanel was well tolerated in subjects with ALS. Although certain adverse events occurred more frequently in the active treatment group, the rate of subject drop-out after nine months did not exceed that seen in other trials. These findings provide strong support for a phase III trial to determine the efficacy of talampanel in subjects with ALS.

Original languageEnglish (US)
Pages (from-to)266-271
Number of pages6
JournalAmyotrophic Lateral Sclerosis
Volume11
Issue number3
DOIs
StatePublished - May 18 2010

Keywords

  • Clinical trials
  • Excitotoxicity
  • Glutamate
  • Therapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Fingerprint Dive into the research topics of 'A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis'. Together they form a unique fingerprint.

  • Cite this

    Pascuzzi, R. M., Shefner, J., Chappell, A. S., Bjerke, J. S., Tamura, R., Chaudhry, V., Clawson, L., Haas, L., & Rothstein, J. D. (2010). A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis, 11(3), 266-271. https://doi.org/10.3109/17482960903307805